Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT00843271

Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA

The purpose of the MESA Lung Study is to assess the role of endothelial dysfunction and genetic susceptibility to subclinical COPD and emphysema.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Chronic Obstructive Pulmonary Disease (COPD) Chronic Disease Disease Attributes Emphysema Endothelial Dysfunction Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

45 year–84 year

Sex eligibility

All sexes

Study type

Observational

About this study

Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD and emphysema that might lead to the development of better therapies for COPD.

MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A random sample of MESA participants active at Exam 3 and/or 4.

Exclusion criteria

  • MESA participants without MESA Exam 3 or 4 measurements.
  • MESA participants without FMD measurements in Exam 1.
  • MESA participants who have not consented to genetic testing.

Treatment and study plan

Primary outcomes

  1. Lung Function (FEV1 (L), FEV1/FVC (%))

    Time frame: Up to 13 years

Secondary outcomes

  1. Lung Density/Percent emphysema on CT (%)

    Time frame: Up to 13 years

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG) (MESA Lung ClinCoordCtr IRB)

Acronym: MESA-LUNG

Important dates

Study start
2004
Primary completion
2027
Study completion
2027
First posted
Feb 13, 2009
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.